home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9601.ZIP
/
M9610508.TXT
< prev
next >
Wrap
Text File
|
1996-01-30
|
2KB
|
39 lines
Document 0508
DOCN M9610508
TI Prospective study of antigenemia, plasma viremia and lymphocytic viremia
in HIV-infected hemophiliacs.
DT 9601
AU Melon Garcia S; de Ona Navarro M; Rodriguez Pinto C; Fernandez Urgelles
M; Martinez Gutierrez A; de la Iglesia P; Mendez Garcia FJ; Microbiology
Service, Hospital Central de Asturias, Oviedo,; Spain.
SO Eur J Clin Microbiol Infect Dis. 1995 May;14(5):400-5. Unique Identifier
: AIDSLINE MED/96039816
AB A total of 186 blood samples from 24 HIV-1 seropositive hemophiliac
patients, monitored every four months for 29 months, were investigated
for the presence of viral antigen in plasma. In addition, peripheral
blood mononuclear cells (PBMC) were cultured for HIV-1, using normal
PBMC as a target for replication. Antigenemia was detected in 51% of the
patients and from PBMC in 87.5% of the patients. The incidence of HIV
isolation in asymptomatic patients (42.8%) was similar to that found in
symptomatic patients (51.4%). Patients with opportunistic infections had
a higher incidence of lymphocytic viremia (p < 0.05). Plasma viremia was
closely associated (p < 0.05) with low CD4+ counts and infection
progression. The persistence of antigenemia was also a marker of a poor
clinical course. In treated patients, plasma viremia was the marker that
better correlated with the clinical course, and it did not appear during
the first nine months of therapy. Zidovudine doses of > 500 mg/day
significantly lowered the appearance of antigenemia and lymphocytic
viremia (p < 0.05).
DE Adolescence Adult Biological Markers/BLOOD
Hemophilia/*COMPLICATIONS/IMMUNOLOGY Human HIV Antigens/*BLOOD HIV
Infections/*COMPLICATIONS/DRUG THERAPY/IMMUNOLOGY
HIV-1/IMMUNOLOGY/*ISOLATION & PURIF Leukocytes,
Mononuclear/IMMUNOLOGY/VIROLOGY Lymphocytes/IMMUNOLOGY/VIROLOGY
Prognosis Prospective Studies Support, Non-U.S. Gov't
Viremia/*COMPLICATIONS/IMMUNOLOGY Zidovudine/THERAPEUTIC USE JOURNAL
ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).